Clinical Trial Update: A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for SHR-1819 Injection in adolescents with moderate-to-severe atopic dermatitis. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• SHR-1819

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Adolescents With Moderate-to-severe Atopic Dermatitis | Phase 3 | Status: RECRUITING